| Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|---|---|---|---|---|---|
Revenues | ||||||
Collaboration and license agreements | ||||||
0 | 1,619 | 113 | - | 54,705 | 18,796 | 20,067 |
Operating expenses | ||||||
Cost of sales | ||||||
- | 1,619 | 113 | - | - | - | - |
Research and development | ||||||
239,108 | 252,902 | 132,760 | 69,611 | 33,439 | 31,883 | 30,669 |
General and administrative | ||||||
47,474 | 38,102 | 26,148 | 16,718 | 12,462 | 7,674 | 7,217 |
Total operating expenses | ||||||
286,582 | 292,623 | 159,021 | 86,329 | 45,901 | 39,557 | 37,886 |
Gain on license of clazakizumab | ||||||
- | - | 1,050 | - | - | - | - |
Loss from operations | ||||||
-286,582 | -291,004 | -157,858 | -86,329 | 8,804 | -20,761 | -17,819 |
Other income (expense) | ||||||
Interest income | ||||||
8,909 | 2,495 | 1,966 | 702 | 44 | 54 | 101 |
Interest expense | ||||||
17,185 | - | - | - | - | - | 88 |
Foreign currency gain (loss) | ||||||
309 | 223 | -349 | 73 | 15 | -21 | - |
Other income | ||||||
- | 50 | 172 | 84 | 45 | 158 | - |
Change in fair value of derivative liability | ||||||
-1,658 | - | - | - | - | - | - |
Other expense | ||||||
- | - | - | - | - | 43 | - |
Total other income (expense), net | ||||||
-9,625 | 2,768 | 1,789 | 859 | 104 | 148 | 13 |
Net loss before equity in net loss of unconsolidated entity | ||||||
-296,207 | -288,236 | -156,069 | -85,470 | 8,908 | - | - |
Equity in net loss of unconsolidated entity | ||||||
-222 | -643 | -185 | - | - | - | - |
Net loss | ||||||
-296,429 | -288,879 | -156,254 | -85,470 | 8,908 | -20,613 | -17,806 |
Deemed dividends on convertible preferred stock attributable to accretion of beneficial conversion feature | ||||||
29,460 | - | - | - | - | - | - |
Dividends on convertible preferred stock | ||||||
6,045 | - | - | - | - | - | - |
Net loss applicable to common stockholders | ||||||
-331,934 | -288,879 | -156,254 | - | - | - | - |
Net income (loss) per share - basic | ||||||
- | - | - | - | 0.43 | -21.14 | -19.54 |
Net income (loss) per share - diluted | ||||||
- | - | - | - | 0.30 | -21.14 | -19.54 |
Weighted average number of common shares used in net income (loss) per share - basic | ||||||
- | - | - | - | 20,506 | 975 | 911 |
Weighted average number of common shares used in net income (loss) per share - diluted | ||||||
- | - | - | - | 29,427 | 975 | 911 |
Net loss per share applicable to common stockholders - basic and diluted | ||||||
-4.87 | -4.95 | -3.23 | -2.11 | - | - | - |
Weighted average number of common shares used in net loss per share - basic and diluted | ||||||
68,099 | 58,347 | 48,407 | 40,586 | - | - | - |